Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of Oridonin A in the Preparation of Drugs for Treating Hyperuricemia and Anti-Gout

A technology of hyperuricemia and Rubescensin A, applied in the application of Rubescensin A in the preparation of anti-gout drugs for treating hyperuricemia and anti-gout, in the field of pharmaceuticals, to inhibit the activity of xanthine oxidase with a small dosage , significant effect

Active Publication Date: 2021-09-17
ZHENGZHOU UNIV
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, the use of Rubescensine A as the active ingredient in the prevention and / or treatment of hyperuricemia and gout has not been reported

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of Oridonin A in the Preparation of Drugs for Treating Hyperuricemia and Anti-Gout
  • Application of Oridonin A in the Preparation of Drugs for Treating Hyperuricemia and Anti-Gout
  • Application of Oridonin A in the Preparation of Drugs for Treating Hyperuricemia and Anti-Gout

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0027] Effects of oridonin on hyperuricemia induced by yeast powder and potassium oxonate.

[0028] 40 healthy male Kunming mice, weighing 18-20 g, were provided by Animal Experiment Center of Henan Province. The mice were adaptively fed for one week in the SPF grade animal room of the School of Pharmacy, Zhengzhou University, Henan Province, and were divided into 4 groups using the random number table method, with 10 mice in each group, as follows:

[0029] 1. Normal control group;

[0030] 2. Model control group;

[0031] 3. Rubescensine A group;

[0032] 4. Positive control drug group.

[0033] After the adaptation period was over, the drug was given by gavage twice a day in the morning. First, the model control group, Rubescensin A group, and positive control group were given intragastric administration of yeast powder (30g / kg), and the normal control group was given the same amount of normal saline for intragastric administration; 1h later, the Oridonin A group was gi...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the field of medicinal chemistry and relates to the application of oridonin in the preparation of drugs for treating hyperuricemia and anti-gout. The invention provides a new use of oridonin as the sole active ingredient or main active ingredient in the preparation of drugs for treating hyperuricemia and anti-gout. The dosage of oridonin in mice is given by intragastric administration of 10 mg / kg body weight. After administration, it can reduce the level of serum uric acid, inhibit the activity of xanthine oxidase in liver tissue, and produce a therapeutic effect on hyperuricemia. And anti-gout effect, and has the advantages of small dosage, no obvious toxicity to liver and kidney. The invention opens up a new application for the oridonin, and provides a new direction for improving the phenomenon of large side effects of the current anti-gout drugs.

Description

technical field [0001] The invention relates to pharmaceutical technology and belongs to the field of medicinal chemistry, in particular to the application of oridonin in the preparation of drugs for treating hyperuricemia and anti-gout. Background technique [0002] Uric acid, namely 2,6,8-purine trioxide, is the end product of human purine metabolism. Uric acid in the blood is produced by the oxidation of xanthine and hypoxanthine catalyzed by xanthine oxidase from buttermilk (XOD), and plays an important physiological role in protecting nerve cells and maintaining blood pressure. Under a normal purine diet, if the blood uric acid level on an empty stomach is higher than 420 μmol / L for men and 360 μmol / L for women on two different days, it is called hyperuricemia (hypeiuricemia, HUA). Internal deposition, causing histological changes, leading to gout, gouty arthritis, gouty nephropathy, etc. Hyperuricemia is often complicated by cardiovascular diseases, and is closely re...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/352A61P19/06A61K36/53
CPCA61K31/352A61K36/53A61P19/06
Inventor 徐霞王馨迎崔伟琪可钰
Owner ZHENGZHOU UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com